Perspectives on Pharmacogenomic Testing in Psychiatric Care
Stanford Digital Repository · 01.01.2026
DOI: 10.25936/8dzm-ck47 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stanford Digital Repository, erschienen am 01.01.2026. Verfasst von Rachele Hendricks‐Sturrup.
Abstract (Originalsprache)
Anxiety, depression, and other psychiatric illnesses affect over 20% of U.S. adults and over one billion people globally. Treatment for psychiatric disorders involves an extended trial-and-error process aimed at finding the right medications and dosages. A 2020 commentary noted that the aging armamentarium of psychiatric medications carries a 40-60% treatment nonresponse rate. This is in addition to patient complications resulting from treatment noncompliance and/or withdrawal and step therapy approaches that can exacerbate patient symptoms via adverse drug reactions and poor symptom management. When symptoms are exacerbated or poorly managed, frequent re-hospitalizations, adverse events due to inadequate treatment or dose exposure, loss of daily life functioning, and/or loss of income or employment result, driving patient, caregiver, and societal burdens or harm. Often, in pursuit of care and resources, patients with disabling mental illness are left to navigate complex health and social systems with limited neurocognition and high dependency on system- or community-level support. Pharmacogenomic (PGx) testing is a novel molecular testing mechanism with the potential to enable more accurate and timely psychiatric medication selection. PGx testing, whether single- or multi-panel, works by classifying patients into phenotype categories based on how they are likely to metabolize, and thus respond to, medications (e.g., normal metabolizers, ultra rapid metabolizers, poor metabolizers). While not always perfect due to evolving science, some psychiatrists think that PGx test information can be useful as a patient-centered decision support tool used alongside standard treatment protocols. That is, PGx test results can empower clinicians and patients with information that may enable more rapid and precise treatment selection. This is particularly true in instances where a patient is identified a carrier of a genetic variant with known drug response significance based on the latest scientific evidence. Today, there are 41 US Food and Drug Administration labeling sections for three PGx biomarkers implicated in psychiatry (CYP2D6, CYP2C19, SLCO1B1). Clinical practice guidelines also exist alongside a growing body of expert-curated evidence intended to support and guide PGx testing implementation in psychiatry. However, variation in US payer coverage of PGx testing in psychiatry is also observable today, therefore limiting certain insurance beneficiaries’ access to such testing. This variation has been discussed among policymakers considering broadening access to testing via proposed legislation. In our 2024 ELSIconversations series, titled “Pharmacogenomic Testing (PGx) in Psychiatric Care,” Dr. Yankah and I presented the perspectives of clinicians, researchers, regulators, payers, and bioethicists during two sessions (see our first session and second session). This ELSIhub Collection builds on that engagement with literature on the status of implementation, clinical perceptions of and workforce readiness for PGx testing, as well as patient perspectives.
Schlagwörter
Zitieren
APA
Hendricks‐Sturrup, R. (2026). Perspectives on Pharmacogenomic Testing in Psychiatric Care. Stanford Digital Repository. https://doi.org/10.25936/8dzm-ck47
Vancouver
Hendricks‐Sturrup R. Perspectives on Pharmacogenomic Testing in Psychiatric Care. Stanford Digital Repository. 2026. doi:10.25936/8dzm-ck47
BibTeX
@article{HendricksSturrup2026,
author = {Hendricks‐Sturrup, Rachele},
title = {Perspectives on Pharmacogenomic Testing in Psychiatric Care},
journal = {Stanford Digital Repository},
year = {2026},
doi = {10.25936/8dzm-ck47}
}
EUVIMED